CAR-T cell therapy research

This study evaluates PSMA-targeted CAR-Ms in preclinical models, showing tumor regression and safety in xenograft mice.

This study develops a three-step method to generate high-yield CAR NK cells from umbilical cord blood CD34+ HSPCs, reducing CAR engineering costs and enabling therapeutic applications.

This study shows that overexpressing Rab5 prevents CAR internalization by tumors, maintains CAR surface expression, and improves CART efficacy against solid tumors.

This study develops CAR-macrophages from pluripotent stem cell-derived myeloid cell lines for enhanced anti-tumor effects through repeated administration.

This study develops a synthetic biology toolbox to engineer CAR-T cells with tunable controls, enabling safe and effective cancer immunotherapy through fail-safe mechanisms.

This paper engineers one-signal-activated TILs with CD3ζ-CD28 chimeras to enhance antitumor efficacy in immunotherapy.

This study shows that endogenous CD28 signaling is essential for CAR T cell efficacy in multiple myeloma, and transient CD28 blockade may reduce toxicities without compromising long-term survival.

The paper shows that modifying integrin-mediated adhesion in CAR T cells prevents CNS targeting while maintaining anti-tumor activity against Ewing sarcoma.

This paper introduces Ingenui-T, a method for rapid CAR T-cell manufacturing from whole blood, showing comparable or better functional activity than conventional methods.

This paper describes the production of CD62L-selected UCB-derived CAR T cells using machine-based manufacturing, showing high CAR19 expression and anti-leukaemic activity comparable to peripheral blood-derived CAR T cells.

This study demonstrates that de novo-designed minibinders can be adapted to various cell engineering tools, improving antigen detection and cytotoxicity compared to antibody-based systems.

This study designs and tests STAT-activating scaffolds to enhance CAR T cell anti-tumor potency, finding that LASI-3 improves function without lymphoproliferative side effects.

This paper develops velocity receptors (VRs) to enhance CAR T cell migration through solid tumors, improving tumor infiltration and survival.

This study evaluates OAcGD2-CAR T cell immunotherapy for pediatric high-grade gliomas, showing Vδ2 T cells outperform conventional β T cells in eliminating tumor cells.

This study shows that varying CAR-antigen complex span affects CAR-T cell activation and effector responses, with optimal activation occurring at a span matching TCR-pMHC complexes.

This study develops a CRISPR-based method to create rapamycin-resistant CAR-T cells, enabling pharmacological control of their activity in cancer therapy.

This paper introduces a leucine zipper-based sorting system to generate T cells with multiple CARs and switch receptors, enhancing their ability to target heterogeneous tumors.

This study shows that CAR extracellular domains reprogram T-cell metabolism independently of antigen stimulation, with distinct metabolic effects observed between different CARs.

This paper develops a framework called PASCAR to systematically explore CAR-T cell design space using multiscale models and optimization, showing intermediate CAR affinities reduce healthy cell lysis while maintaining tumor cell killing.

This paper develops valency-controlled receptors (VCRs) to enhance CAR functionality by modulating T cell signaling through multivalent ligands, showing improved immune response against tumors.

This paper introduces a novel CAR T cell platform using proximal T cell signaling molecules to enable Boolean logic-gated control, improving efficacy and reducing off-tumor toxicity.

The paper uses mathematical modeling to show that CD28-bearing CARs lead to faster and more consistent T cell responses under variability, with LCK activity influencing response times.

The paper analyzes pan-cancer single-cell transcriptomes to evaluate and identify new CAR targets for head and neck cancer, finding five promising targets with superior selectivity and safety.

This study finds that clonal hematopoiesis mutations, particularly in DNMT3A, TET2, and ASXL1, are linked to increased toxicity in patients undergoing anti-CD19 CAR T-cell therapy for large B-cell lymphoma.

This study evaluates vectofusin-1 as a transduction enhancer for generating murine CAR-T cells, finding it comparable to Retronectin.

speedingCARs uses domain shuffling and single-cell sequencing to engineer CAR T cells, identifying effective variants with diverse transcriptional signatures and T cell phenotypes.

This study identifies brain capillary obstruction and hypoxia as mechanisms of neurotoxicity in CD19-CAR T cell therapy using a mouse model.